Impact of the OncotypeDX score and HER2 RNA PCR levels on HER2-low IHC levels in primary and metastasized tumors

PURPOSE: One-half of hormone receptor-positive (HR +) breast cancer (BC) patients have low expression of HER2 (HER2-low) and may benefit from trastuzumab deruxtecan (TDXd). This study aimed to identify parameters associated with HER2-low levels in primary and metastatic tumors. We specifically sough...

Descripción completa

Detalles Bibliográficos
Autores principales: Feldman, Didi, Sinberger, Liat Anabel, Salmon-Divon, Mali, Ben-Dror, Judith, Shachar, Shlomit Strulov, Sonnenblick, Amir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598997/
https://www.ncbi.nlm.nih.gov/pubmed/37875892
http://dx.doi.org/10.1186/s12885-023-11530-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598997/
https://www.ncbi.nlm.nih.gov/pubmed/37875892
http://dx.doi.org/10.1186/s12885-023-11530-w

Ejemplares similares